1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

Summary

GBI Research, the leading business intelligence provider, has released its latest research, ‘Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting’, which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes -
- A brief introduction to NHL, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
- In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
- A comprehensive review of the pipeline for NHL, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
- Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Understand the NHL pipeline and the factors that indicate that it is becoming more innovative
- Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
- Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country - strategy through an understanding of key drivers and barriers in the NHL market
- Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table Of Contents

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 11
2.4 Diagnosis 12
2.4.1 Biopsy 12
2.4.2 Laboratory molecular tests 12
2.4.3 Imaging tests 13
2.5 Classification 13
2.5.1 B-Cell lymphomas 14
2.5.2 T-Cell Lymphomas 16
2.6 Epidemiology 17
2.7 Prognosis and Disease Staging 18
2.7.1 Staging 19
2.8 Treatment Options 20
2.8.1 Surgery and Radiation Therapy 20
2.8.2 Stem Cell Transplantation 20
2.8.3 Pharmacological 20
2.8.4 Treatment Algorithms and Prescribing Habits 22
3 Marketed Products 24
3.1 Therapeutic Landscape 24
3.1.1 Immunotherapies 24
3.1.2 Targeted Therapies 29
3.1.3 Chemo-Regimens 32
3.2 Comparative Efficacy and Safety (Marketed Products) 34
4 Pipeline Products 37
4.1 Overall Pipeline 37
4.2 Pipeline Analysis by Molecule Type 38
4.3 Pipeline Analysis by Mechanism of Action 39
4.4 Clinical Trials 41
4.4.1 Failure Rate 41
4.4.2 Patient Enrollment and Clinical Trial Size 42
4.4.3 Duration 43
4.5 Promising Drug Candidates in the Pipeline 44
4.5.1 Idelalisib (GS-1101) - Gilead Sciences 44
4.5.2 Imbruvica (Ibrutinib) - Pharmacyclics/Janssen Biotech 45
4.5.3 Gazyva (Obinutuzumab) - Roche 45
4.5.4 Revlimid (lenalidomide) - Celgene 46
4.5.5 Afinitor (everolimus) - Novartis 47
4.6 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Non-Hodgkin Lymphoma Pipeline 48
5 Market Forecast to 2020 51
5.1 Geographical Markets 51
5.1.1 APAC Market 51
5.1.2 India 52
5.1.3 Australia 55
5.1.4 China 58
5.1.5 Japan 60
5.2 Drivers and Barriers for the Disease Market 63
5.2.1 Drivers 63
5.2.2 Barriers 64
6 Deals and Strategic Consolidations 65
6.1 Major Co-development Deals 67
6.1.1 Roche Signs an Agreement with GlycArt and Genentech 68
6.1.2 Cell Therapeutics Enters Agreement with Bayer 68
6.1.3 Chugai Enters Co-development Agreement with Nippon Shinyaku for GA101 68
6.1.4 GlaxoSmithKline Enters Co-development Agreement with Genmab 69
6.1.5 Biogen Idec Enters Co-development Agreement with Genentech 69
6.1.6 Seattle Genetics Enters Co-development Agreement with Millennium 69
6.2 Major Licensing Deals 69
6.2.1 Spectrum Enters Licensing Agreement with Bayer for Zevalin 70
6.2.2 Janssen Biotech Enters Licensing Agreement with Pharmacyclics for PCI-32765 70
6.2.3 Lundbeck Enters Licensing Agreement with Cephalon 71
6.2.4 TG Therapeutics Enters Licensing Agreement with Ildong for Ublituximab 71
6.2.5 Provenance Enters Licensing Agreement with Merck Serono 71
6.2.6 Cephalon Enters Licensing Agreement with SymBio 71
6.2.7 Genentech Enters Licensing Agreement with Seattle Genetics 71
7 Appendix 72
7.1 Market Definitions 72
7.2 Abbreviations 72
7.3 Bibliography 75
7.4 Pipeline Tables 78
7.4.1 Discovery 78
7.4.2 Preclinical 79
7.4.3 Investigational New Drug-Filed 81
7.4.4 Phase I 82
7.4.5 Phase II 85
7.4.6 Phase III 89
7.5 Market Forecasts to 2020 90
7.5.1 Asia-Pacific 90
7.5.2 India 90
7.5.3 Australia 91
7.5.4 China 91
7.5.5 Japan 92
7.6 Research Methodology 92
7.6.1 Coverage 92
7.6.2 Secondary Research 93
7.6.3 Primary Research 93
7.6.4 Therapeutic Landscape 93
7.6.5 Geographical Landscape 95
7.6.6 Pipeline Analysis 96
7.7 Expert Panel Validation 96
7.8 Contact Us 96
7.9 Disclaimer 961.1 List of Tables
Table 1: Non-Hodgkin Lymphoma Therapeutics, Most Common Chromosomal Aberrations Associated With NHL 12
Table 2: Non-Hodgkin Lymphoma Therapeutics, IWF Classification of Lymphoproliferative Diseases 14
Table 3: Non-Hodgkin Lymphoma Market, Classification of Non-Hodgkin Lymphoma 17
Table 4: Non-Hodgkin Lymphoma Market, IPI Good and Poor Prognostic Factors 18
Table 5: Non-Hodgkin Lymphoma Market, Ann Arbor Staging System for Lymphoma 19
Table 6: Non-Hodgkin Lymphoma Market, Commonly Used Chemo-Regimens 21
Table 7: Non-Hodgkin Lymphoma Market, Common Symptoms of Non-Hodgkin Lymphoma 26
Table 8: Non-Hodgkin Lymphoma Market, Endpoints of Various Chemotherapeutic Regimens (%) 33
Table 9: Non-Hodgkin Lymphoma Market, Efficacy Comparison of R-CHOP vs. CHOP 34
Table 10: Non-Hodgkin Lymphoma Market, Efficacy Comparison of CVP vs R-CVP 34
Table 11: Non-Hodgkin Lymphoma Market, Global, Average Clinical Trial Duration (Months) 43
Table 12: Non-Hodgkin Lymphoma Market, Global, Deals and Strategic Consolidations, 2006-2014 65
Table 13: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Discovery), 2014 78
Table 14: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Preclinical), 2014 79
Table 15: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (IND-filed), 2014 81
Table 16: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase I), 2014 82
Table 17: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase II), 2014 85
Table 18: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase III), 2014 89
Table 19: Non-Hodgkin Lymphoma Market, Asia-Pacific, Market Forecast, 2013-2020 90
Table 20: Non-Hodgkin Lymphoma Market, India, Market Forecast, 2013-2020 90
Table 21: Non-Hodgkin Lymphoma Market, Australia, Market Forecast, 2013-2020 91
Table 22: Non-Hodgkin Lymphoma Market, China, Market Forecast, 2013-2020 91
Table 23: Non-Hodgkin Lymphoma Market, Japan, Market Forecast, 2013-2020 921.2 List of Figures
Figure 1: Non-Hodgkin Lymphoma Market, Asia-Pacific, Distribution of Prevalence Population, 2013-2020 18
Figure 2: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Indolent Non-Hodgkin Lymphoma, 2014 22
Figure 3: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Aggresive Non-Hodgkin Lymphoma, 2014 23
Figure 4: Non-Hodgkin Lymphoma Market, Global, Rituxan, Annual Sales ($bn), 2006-2013 25
Figure 5: Non-Hodgkin Lymphoma Market, Global, Adcetris, Annual Sales ($m), 2011-2013 27
Figure 6: Non-Hodgkin Lymphoma Market, Global, Velcade, Annual Sales ($bn), 2007-2013 30
Figure 7: Non-Hodgkin Lymphoma Market, Global, Istodax, Annual Sales ($m), 2010-2013 31
Figure 8: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2014 36
Figure 9: Non-Hodgkin Lymphoma Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2014 38
Figure 10: Non-Hodgkin Lymphoma Market, Global, Pipeline by Molecule Type and Stage of Development, 2014 39
Figure 11: Non-Hodgkin Lymphoma Market, Global, Pipeline by Mechanism of Action, 2014 40
Figure 12: Non-Hodgkin Lymphoma, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2014 41
Figure 13: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Failure Rate (%), 2014 42
Figure 14: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Size (Participants), 2014 43
Figure 15: Non-Hodgkin Lymphoma Market, Global, Pipeline Clinical Trial Duration (Months), 2014 44
Figure 16: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Pipeline Products (Heat Map), 2014 50
Figure 17: Non-Hodgkin Lymphoma Market, Asia-Pacific, Market Size, 2013-2020 52
Figure 18: Non-Hodgkin Lymphoma Market, India, Treatment Usage Pattern (‘000), 2013-2020 53
Figure 19: Non-Hodgkin Lymphoma Market, India, Annual Cost of Therapy ($), 2013-2020 54
Figure 20: Non-Hodgkin Lymphoma Market, India, Market Size ($m), 2013-2020 55
Figure 21: Non-Hodgkin Lymphoma Market, Australia, Treatment Usage Pattern (‘000), 2013-2020 56
Figure 22: Non-Hodgkin Lymphoma Market, Australia, Annual Cost of Therapy ($‘000), 2013-2020 57
Figure 23: Non-Hodgkin Lymphoma Market, Australia, Market Size ($m), 2013-2020 58
Figure 24: Non-Hodgkin Lymphoma Market, China, Treatment Usage Pattern (‘000), 2013-2020 59
Figure 25: Non-Hodgkin Lymphoma Market, China, Annual Cost of Therapy, 2013-2020 59
Figure 26: Non-Hodgkin Lymphoma Market, China, Market Size ($m), 2013-2020 60
Figure 27: Non-Hodgkin Lymphoma Market, Japan, Treatment Usage Pattern (‘000), 2013-2020 61
Figure 28: Non-Hodgkin Lymphoma Market, Japan, Annual Cost of Therapy ($‘000), 2013-2020 62
Figure 29: Non-Hodgkin Lymphoma Market, Japan, Market Size ($m), 2013-2020 63
Figure 30: Non-Hodgkin Lymphoma Market, Global Deals by Value, Year and Stage of Development, 2006-2014 66
Figure 31: Non-Hodgkin Lymphoma Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2014 67
Figure 32: Non-Hodgkin Lymphoma Market, Global, Co-development Deals by Geography, 2006-2014 68
Figure 33: Non-Hodgkin Lymphoma Market, Global, Licensing Deals by Geography, 2006-2014 70
Figure 34: GBI Research Market Forecasting Model 95

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Hodgkin’s lymphoma (HL) - Market Insights, Epidemiology and Market Forecast-2023

Hodgkin’s lymphoma (HL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Hodgkin’s lymphoma (HL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Hodgkin’s lymphoma (HL) ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.